ag-490 has been researched along with Uterine-Cervical-Neoplasms* in 3 studies
3 other study(ies) available for ag-490 and Uterine-Cervical-Neoplasms
Article | Year |
---|---|
Functional regulatory role of STAT3 in HPV16-mediated cervical carcinogenesis.
Signal transducer and activator of transcription 3 (STAT3) is an oncogenic transcription factor constitutively active and aberrantly expressed in cervical cancer. However, the functional role of STAT3 in regulation of HPV's viral oncogene expression and downstream events associated with cervical carcinogenesis is not known. Our present study performed on HPV16-positive cervical cancer cell lines (SiHa and CaSki) and primary tumor tissues revealed a strong positive correlation of constitutively active STAT3 with expression of HPV16 E6 and E7 oncoproteins and a negative association with levels of p53 and pRB. Pharmacologic targeting of STAT3 expression in cervical cancer cell lines either by STAT3-specific siRNA or blocking its tyrosine phosphorylation by AG490 or curcumin led to dose-dependent accumulation of p53 and pRb in cervical cancer cells. Interestingly, the suppression of STAT3 expression or activation was associated with the gradual loss of HPV16 E6 and E7 expression and was accompanied by loss of cell viability. The viability loss was specifically high in HPV16-positive cells as compared to HPV negative C33a cells. These findings substantiate the regulatory role of STAT3 in HPV16-mediated cervical carcinogenesis. Leads obtained from the present study provide a strong rationale for developing novel STAT3-based approaches for therapeutic interventions against HPV infection to control cervical cancer. Topics: Carcinogenesis; Caspase 3; Cell Line, Tumor; Curcumin; Electrophoretic Mobility Shift Assay; Female; Flow Cytometry; Gene Expression Regulation, Viral; Human papillomavirus 16; Humans; Immunoblotting; Immunohistochemistry; Oncogene Proteins, Viral; RNA, Small Interfering; STAT3 Transcription Factor; Tetrazolium Salts; Thiazoles; Tyrphostins; Uterine Cervical Neoplasms | 2013 |
The tyrphostin B42 inhibits cell proliferation and HER-2 autophosphorylation in cervical carcinoma cell lines.
The HER family receptors have an important role controlling cell growth and differentiation. Although the activity of the HER-2 receptor is strictly controlled in normal cells, its overexpression plays a pivotal role in transformation and tumorigenesis. Constitutive phosphorylation of HER-2 protein has been implicated in conferring uncontrolled growth to mammary cancer cells, and to a lesser extent, with adenocarcinoma of uterus, cervix, fallopian tube, and endometrium. This study addresses the role of HER-2 in cervical carcinoma. Firstly, we demonstrate the presence of HER-2 protein expression by flow cytometry in two new cervical carcinoma cell lines CALO and INBL. Secondly, we use the specific tyrosine kinase inhibitors, Tyrphostins to examine HER-2 regulation by the crystal violet assay. Thirdly, we use western blot analysis to assess the state of HER-2 phosphorylation. The most efficient agent, Tyrphostin B42, known as an inhibitor of epithelial growth factor receptor, arrested cervical carcinoma cell lines growth in vitro at micromolar concentrations within 72 h of application. Tyrphostin B42 inhibited the HER2 signal-regulated kinase pathway, as observed by the reduction in the phosphorylated forms of HER2. The loss of phosphorylated forms of HER2 at early time points after Tyrphostin B42 application was associated with suppression of cell growth. Thus, the inhibition of the proliferation of our cervical carcinoma cell lines by Tyrphostin B42 is associated with inhibition of HER2 protein kinase signal. Topics: Antineoplastic Agents; Cell Proliferation; Female; Humans; Immunoblotting; Immunoprecipitation; Phosphorylation; Protein-Tyrosine Kinases; Receptor, ErbB-2; Tumor Cells, Cultured; Tyrosine; Tyrphostins; Uterine Cervical Neoplasms | 2008 |
Erythropoietin induces cancer cell resistance to ionizing radiation and to cisplatin.
Recent studies suggest that erythropoietin plays an important role in the process of neoplastic transformation and malignant phenotype progression observed in malignancy. To study the role of erythropoietin and its receptor (EPOR) on the response of cancer cells in vitro, we used two solid tumor cell lines, namely the human malignant glioma cell line U87 and the primary cervical cancer cell line HT100. All experiments were done with heat-inactivated fetal bovine serum in order to inactivate any endogenous bovine erythropoietin. The expression of the EPOR in these cells was confirmed with immunoblot techniques. The addition of exogenous recombinant human erythropoietin (rhEPO) induces the cancer cells to become more resistant to ionizing radiation and to cisplatin. Furthermore, this rhEPO-induced resistance to ionizing radiation and to cisplatin was reversed by the addition of tyrphostin (AG490), an inhibitor of JAK2. Our findings indicate that rhEPO result in a significant, JAK2-dependent, in vitro resistance to ionizing radiation and to cisplatin in the human cancer cells lines studied in this report. Topics: Animals; Antineoplastic Agents; Cattle; Cisplatin; Drug Resistance, Neoplasm; Erythropoietin; Female; Glioma; Humans; Janus Kinase 2; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Radiation Tolerance; Radiation, Ionizing; Receptors, Erythropoietin; Recombinant Proteins; Tumor Cells, Cultured; Tyrphostins; Uterine Cervical Neoplasms | 2004 |